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Lead toxicity remains a critical environmen-
tal health issue, given the widespread nature
of lead exposure from both community and
occupational exposures as well as the demon-
stration of lead’s deleterious effect on multi-
ple organ systems at ever lower levels of
exposure.
One important question in the study of
lead toxicity that has only recently begun
receiving attention involves understanding the
factors that explain differences in symptoms
among individuals who have similar lead
exposures. In addition, significant variation
has been observed in the relationship between
biologic markers of lead exposure and mea-
sures of organ dysfunction. Understanding
the nature of this variation could also lead to a
more profound understanding of the mecha-
nism of toxicity of lead.
A genetic polymorphism in the δ -amino-
levulinic acid dehydratase (ALAD) gene has
been suggested (1,2) to modify the kinetics
and distribution of lead (and therefore its
toxicity). This gene codes for the second
enzyme in the biosynthetic pathway of heme
(3,4). In 1981, Battistuzzi et al. (3) showed
that human ALAD protein is a polymorphic
enzyme. Subsequently, Wetmur et al. (4)
characterized the molecular nature of this
polymorphism, showing it to be caused by a
G-to-C transversion in nucleotide 177. This
produces coding for lysine rather than aspar-
ganine. Although initially Battistuzzi et al.
(3) noted no detectable difference in the in
vitro activities of the variant enzymes (ALAD
1-1, ALAD 1-2, or ALAD 2-2) in erythro-
cytes, Bergdahl et al (5) found that the
ALAD-2 subunit binds lead more tightly
than does the ALAD-1 subunit.
Epidemiologic studies have suggested
that among lead-exposed workers (6,7) and
environmentally exposed children (6), indi-
viduals with either the ALAD 1-2 or 2-2
genotype had blood lead levels that were sig-
niﬁcantly higher than the blood lead levels of
individuals with the ALAD 1-1 genotype.
These findings suggest that the ALAD-2
polypeptide binds lead more tightly and
effectively than ALAD-1. However, Smith et
al. (8) did not find any meaningful differ-
ence in mean blood lead concentration
between ALAD-2 carriers and those who
were homozygous for the ALAD-1 allele
among 688 members of a construction trade
union. The relatively low blood lead levels of
these union members [mean ± standard
deviation (SD): 7.8 ± 3.6 µg/dL] led the
authors to suggest that the ALAD polymor-
phism may inﬂuence lead kinetics, but only
at relatively high levels of exposure. In stud-
ies of lead smelter workers whose blood lead
levels ranged from 20–30 µg/dL, Bergdahl et
al. (9) did not ﬁnd any signiﬁcant differences
in bone and blood lead levels by genotype
among 123 subjects, but Fleming et al. (10)
found that lead workers with the ALAD 1-
2/2-2 had signiﬁcantly higher blood lead lev-
els than those with ALAD 1-1 among 381
subjects. 
In this study, we investigated the impact
of the ALAD polymorphism on lead levels in
both blood and bone among participants of
the Normative Aging Study (NAS) (11).
This is a well-studied cohort of men, now
middle-aged and elderly, who have had gen-
eral community (nonoccupational) expo-
sures to lead. Among the advantages of this
study are the relatively large sample size (n =
726), the availability of a host of other well-
validated demographic and lifestyle data, and
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Articles
Recent research has indicated that a polymorphic variant of δ -aminolevulinic acid dehydratase
(ALAD) may inﬂuence an individual’s level of lead in bone and blood and, as a result, may also
inﬂuence an individual’s susceptibility to lead toxicity. In this study, we investigated whether this
ALAD polymorphism is associated with altered levels of lead in bone and blood among 726 mid-
dle-aged and elderly men who had community (nonoccupational) exposures to lead. We measured
levels of blood and bone lead by graphite furnace atomic absorption spectroscopy and a K X-ray
ﬂuorescence (KXRF) instrument, respectively. We determined the ALAD MspI polymorphism in
exon 4 by a polymerase chain reaction restriction fragment length polymorphism (RFLP). Of the
726 subjects, 7 (1%) and 111 (15%) were, respectively, homozygous and heterozygous for the
variant allele. The mean (SD) of blood lead (micrograms per deciliter), cortical bone (tibia) lead
(micrograms per gram), and trabecular bone (patella) lead (micrograms per gram) were 6.2 (4.1),
22.1 (13.5), and 31.9 (19.5) in subjects who did not have the variant allele (ALAD 1-1), and 5.7
(4.2), 21.2 (10.9), and 30.4 (17.2) in the combined subjects who were either heterozygous or
homozygous for the variant allele (ALAD 1-2 and ALAD 2-2). In multivariate linear regression
models that controlled for age, education, smoking, alcohol ingestion, and vitamin D intake, the
ALAD 1-1 genotype was associated with cortical bone lead levels that were 2.55 µg/g [95% conﬁ-
dence interval (CI) 0.05–5.05] higher than those of the variant allele carriers. We found no signif-
icant differences by genotype with respect to lead levels in trabecular bone or blood. In stratiﬁed
analyses and a multivariate regression model that tested for interaction, the relationship of trabec-
ular bone lead to blood lead appeared to be signiﬁcantly modiﬁed by ALAD genotype, with vari-
ant allele carriers having higher blood lead levels, but only when trabecular bone lead levels
exceeded 60 µg/g. These results suggest that the variant ALAD-2 allele modiﬁes lead kinetics pos-
sibly by decreasing lead uptake into cortical bone and increasing the mobilization of lead from
trabecular bone. Key words: blood, bone, δ -aminolevulinic acid dehydratase, lead. Environ Health
Perspect 109:827–832 (2001). [Online 13 August 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p827-832hu/abstract.htmlthe use of a K X-ray fluorescence (KXRF)
instrument for making in vivo measurements
of bone lead. These measurements are well-
validated (12) and have produced data for a
number of previous successful studies on
low-level lead toxicity and biomarker deter-
minants (13–16). We examined the relation-
ship of the ALAD polymorphism to bone
and blood lead levels. In addition, we con-
ducted exploratory analyses to see if the
ALAD polymorphism modiﬁes the relation-
ship of bone or blood lead levels to any of
their well-known determinants.
This study was approved by the Human
Subjects Committees of the Brigham and
Women’s Hospital and the Harvard School
of Public Health.
Materials and Methods
Study subjects. The NAS is a longitudinal
study of aging established by the U.S.
Veterans Administration in 1963 (11).
Healthy male volunteers from the Greater
Boston (Massachusetts) area were screened at
entry and accepted into the study if they had
no history of heart disease, hypertension,
diabetes mellitus, cancer, peptic ulcer, gout,
recurrent asthma, bronchitis, or sinusitis.
Men who presented with either systolic
blood pressure >140 mmHg or diastolic
blood pressure >90 mmHg at entry were dis-
qualified. Between 1963 and 1968, 2,280
men who met the entry criteria were
enrolled, ranging in age from 21 to 81 years,
with mean age of 42 years at entry. Study
participants were asked to return for exami-
nations every 3–5 years. At each visit, exten-
sive physical examination, laboratory,
anthropometric, and questionnaire data were
collected. Beginning in 1991, during the
course of each continuing participant’s regu-
larly scheduled evaluation at the Department
of Veterans Affairs Outpatient clinic in
Boston, a fresh blood specimen was obtained
for measurement of lead, and permission was
sought to take KXRF bone lead measure-
ments. Consenting individuals reported to
the outpatient Clinical Research Center of
the Brigham and Women’s Hospital in
Boston.
Blood and bone lead measurements. We
obtained blood samples and analyzed by
graphite furnace atomic absorption spec-
troscopy (GF-AAS; ESA Laboratories,
Chelmsford, MA). Values below the mini-
mum detection limit of 1 µg/dL were coded
as 0.5 µg/dL. We calibrated the instrument
after every 21 samples with National
Institute of Standards and Technology
(Gaithersburg, MD) materials. We ran 10%
of samples in duplicate; at least 10% of the
analyses were controls and 10% blanks. In
tests on reference samples from the Centers
for Disease Control and Prevention (Atlanta,
GA), precision (the coefﬁcient of variation)
ranged from 8% for concentrations from 10
to 30 µg/dL to 1% for higher concentra-
tions. In comparison with a National Bureau
of Standards target of 5.7 µg/dL, 24 mea-
surements by this method gave a mean of
5.3 µg/dL (SD 1.23 µg/dL). 
We took bone lead measurements at two
bone sites, the mid-tibial shaft and the
patella, with an ABIOMED KXRF instru-
ment (ABIOMED, Inc., Danvers, MA). The
tibia and patella have been targeted for bone
lead research because these two bones consist
mainly of pure cortical and trabecular bone,
respectively, which represent the two main
bone compartments. A technical description
and validity speciﬁcations of this instrument
have been published elsewhere (12,17). This
instrument provides an unbiased estimate of
bone lead levels (normalized to bone mineral
content as micrograms of lead per gram of
bone mineral) and an estimate of the uncer-
tainty associated with each measurement
(equivalent to a single SD if multiple mea-
surements were taken). Negative estimates of
bone lead concentration may occur for lead
values close to zero. The technicians who
measured the bone lead were blinded to the
participant’s health status.
ALAD exon 4 genotypes analysis. We
determined the ALAD polymorphism in
exon 4 by polymerase chain reaction (PCR)
and restriction fragment length polymor-
phism (RFLP), according to the method of
Schwartz et al. (18). We performed PCRs in
duplicate with blank controls included in
each set.
Statistical analyses. We first compared
characteristics of subjects who had all data of
interest, including genotypes and blood and
bone lead levels, with subjects who were not
included in this analysis because of missing
data. Gene frequencies and tests for Hardy-
Weinberg equilibrium were calculated. Only
7 (1%) subjects in this population were clas-
siﬁed as ALAD 2-2, so we combined ALAD
1-2 and ALAD 2-2 into one category (ALAD
1-2/2-2) for most of the subsequent analyses.
We compared the distributions of demo-
graphic and lifestyle characteristics (as cate-
gories) and bone and blood lead levels (as
continuous variables) by genotype (ALAD 1-
1 versus ALAD 1-2/2-2), and tested the dif-
ferences using chi-square and Student’s t-test
statistics. We adjusted dietary vitamin D for
total caloric intake and divided it into quin-
tiles, as we had done before (15). We used
multivariate linear regression to model deter-
minants of tibia lead, patella lead, and blood
lead; we began with core models including
determinants we had identiﬁed in previously
published research (13,15). For the tibia and
patella lead, these core-model determinants
included age, educational levels, cumulative
smoking, alcohol consumption, and dietary
intake of vitamin D; for blood lead, these
core-model determinants included age, cur-
rent smoking status, current alcohol con-
sumption, dietary intake of vitamin C, and
patella lead [the major internal bone source
of circulating lead (13,15)]. We repeated
each of these regressions after adding a term
for genotype (ALAD 1-1 vs. ALAD 1-2/2-2).
To assess whether genotype may serve as
an effect modifier (versus an independent
determinant) of bone lead, we also compared
the β -estimates of core-model determinants
in regressions of tibia and patella bone lead
that were stratiﬁed by genotype (ALAD 1-1
versus ALAD 1-2/2-2). If a core-model β -
estimate was markedly different between
genotypes, we ran an additional exploratory
regression of the entire sample; the regres-
sion included a cross-product term that
tested for interaction between genotype and
the core-model determinant of interest. This
allowed us to test for the signiﬁcance of the
interaction term.
In each of the above regressions, we ran
generalized additive models for continuous
covariates to examine the shape of associa-
tions with bone lead and blood lead. These
analyses allowed us to assess for potential
nonlinearities and the need to transform
these covariates.
All data were analyzed using the SAS and
S-plus statistical packages (19). All p-values
reported are two-sided.
Results
The 776 NAS subjects who participated in
the KXRF bone lead study were comparable
to the 1,532 NAS subjects who were seen for
their regularly scheduled visits between 1991
and 1995 with respect to distributions of
age, race, education, smoking status, con-
sumption of alcohol, retirement status, and
blood lead level, as noted in an earlier report
(15). Of these 776 NAS subjects, 726 had
information on genotype status. We found
no signiﬁcant differences in distributions of
age, education, alcohol consumption, and
blood and bone lead levels among subjects
with and without genotype (data not
shown). Nine of 726 (1%) and 8 of 50 sub-
jects (16%) with and without genotype,
respectively, did not provide information on
smoking status. However, among the sub-
jects with information on smoking status,
the distribution of never, former, and cur-
rent smokers was not significantly different
between those with and those without geno-
type information.
The prevalence (number) of ALAD 1-1,
ALAD 1-2, and ALAD 2-2 was 83.5%
(580), 15.5% (108), and 1.0% (7), respec-
tively. The distribution of the different
ALAD genotypes among the 726 NAS study
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expected frequencies (chi-square = 0.28; df =
2; p = 0.87). 
Table 1 shows the demographic charac-
teristics and blood and bone lead levels cate-
gorized by genotype. The ALAD 1-1
genotype was associated with a higher per-
centage of current smokers and drinkers than
the ALAD 1-2/2-2 genotype. Blood lead lev-
els in this population were relatively low, as
expected, with a mean (SD) of 6.2 (4.1)
µg/dL. The mean (SD) blood lead of individ-
uals with the ALAD 1-1 genotype [6.3 (4.1)
µg/dL], was signiﬁcantly higher than that of
the variant allele carriers [5.7 (4.2) µg/dL (t-
statistic = 2.11, p = 0.04)]. We found no dif-
ferences in mean bone lead levels, including
tibia and patella lead as well as tibia and
patella lead adjusted by age. We also did not
ﬁnd any association between the variant allele
and the difference between tibia and patella
bone lead concentrations (the cortical-trabec-
ular bone lead differential, Table 1), a para-
meter that had previously been found to
differ by genotype among lead-exposed con-
struction workers (8).
As in our previous investigation (15),
older age, lower education level, higher
pack-years of cigarette smoking, and low
intake of vitamin D were important predic-
tors of bone lead levels in the core regression
models (Table 2 Model A, Table 3 Model
A). We found that the ALAD genotype sig-
nificantly influenced tibia lead, but not
patella lead. Subjects with the ALAD 1-2/2-
2 genotype had tibia lead levels that were
2.55 µg/g (95% CI, 0.05–5.05) lower than
those with the ALAD 1-1 genotype after
adjusting for other covariates (Table 2
Model B). In the regression models stratiﬁed
by presence or absence of variant allele, hav-
ing a less-than-high school education was
associated with a mean tibia lead level that
was substantially higher among the ALAD 1-
1 genotype subjects (8.15 µg/g) than among
the ALAD 1-2/2-2 genotype subjects (4.88
µg/g; Table 4 Models C and D). In addi-
tion, dietary intake of Vitamin D in the
highest versus the lowest quintiles was asso-
ciated with a mean difference in tibia lead
level that was substantially greater among the
ALAD 1-1 genotype subjects (–7.31 µg/g)
than among the ALAD 1-2/2-2 genotype
subjects (–3.14 µg/g; Table 4 Models C and
D). However, no such differences were seen
in the models of patella lead stratified by
genotype (Table 5 Models C and D). In
subsequent models of tibia lead that re-com-
bined the ALAD 1-1 and ALAD 1-2/2-2
groups, interaction terms for genotype with
less-than-high school education and interac-
tion terms for genotype with dietary intake
of vitamin D in the highest quintile failed to
reach statistical significance (data not
shown).
In the core model of blood lead, high
intakes of Vitamin C and iron were associ-
ated with low blood lead, as seen before
(15). In addition, higher patella bone lead
was associated with higher blood lead and
was the dominant statistical determinant of
blood lead (partial R2 of 0.14; total adjusted
R2 of 0.19). When added to this core model,
a term for presence or absence of variant
allele was not associated with any meaning-
ful change in blood lead. However, in the
models of blood lead that were stratiﬁed by
the ALAD genotype (Table 6 Models D and
E), the effect estimate that was associated
with each microgram per gram increase in
patella bone lead was substantially higher
among the ALAD 1-2/2-2 genotype subjects
(0.15 µg/dL) than among the ALAD 1-1
genotype subjects (0.07 µg/dL). In a model
that re-combined the ALAD 1-1 and ALAD
1-2/2-2 genotype subjects (Table 7 Model
C), an interaction term for ALAD 1-2/2-2
genotype and patella bone lead was associ-
ated with a significantly higher blood lead
level. In the same model, the term for ALAD
1-2/2-2 genotype alone was associated with a
significantly lower blood lead level. In a
smoothed plot of blood lead in relation to
patella lead that was stratified by genotype
and adjusted for other covariates in the
model (Figure 1), this interaction can be
appreciated as, among the ALAD 1-2/2-2
genotype individuals, a lower blood lead
when bone lead levels are below 40 µg/g,
and a higher blood lead level when bone lead
levels are above 60 µg/g.
Discussion
In this study, we found no signiﬁcant differ-
ences among participants according to
ALAD genotype with respect to levels of lead
in blood or patella (trabecular) bone.
Although a mean blood lead level that was
slightly higher among ALAD 1-1 than
among ALAD 1-2/2-2 genotype individuals
was suggested in the bivariate analyses, this
difference disappeared in the multivariate
regression analysis and may have been
caused by confounding by patterns of alco-
hol ingestion and smoking.
On the other hand, we found in the mul-
tivariate analyses that tibia (cortical) bone
lead levels were signiﬁcantly lower among the
ALAD 1-2/2-2 than in the ALAD 1-1 geno-
type individuals, with a mean difference that
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Table 1. Demographic characteristics and blood and bone lead concentrations by genotypes among 726
study subjects, 1991–1995.
Genotype
Variable ALAD 1-1 (n = 608) ALAD 1-2/2-2 (n = 118) p-Value
Age (years)a
47-59 100 (16) 14 (12) 0.46
60-69 297 (49) 61 (52)
≥ 70 211 (35) 43 (36)
Educationa
≤ High school 326 (54) 68 (58) 0.75
Some college/technical school 86 (14) 15 (13)
> College 168 (28) 31 (26)
Missing 28 (4) 4 (3)
Current smoking statusa
Never smoker 175 (29) 42 (36) 0.04
Former smoker 366 (60) 72 (61)
Current smoker 59 (10) 3 (3)
No information 8 (1) 1 (1)
Cumulative smoking (pack years)a
0 175 (29) 42 (36) 0.49
1–20 153 (25) 28 (24)
> 20 248 (41) 44 (37)
No information 32 (5) 4 (3)
Currently consuming ≥ 2 alcoholic drinks/daya
Yes 136 (22) 15 (13) 0.02
No 472 (78) 103 (87)
Blood lead (µg/dL)b 6.3 ± 4.1 5.7 ± 4.2 0.04
(0, 5, 35) (0, 5, 27)
Bone lead (µg/g)b
Tibia 22.2 ± 13.9 21.2 ± 10.9 0.62
(–3, 19, 126) (3, 19.5, 67)
Patella 32.2 ± 19.9 30.4 ± 17.2 0.36
(1, 28, 165) (–10, 27, 85)
Adjusted tibiab 22.3 ± 13.1 20.5 ± 10.6 0.17
(–8.5, 20, 121.3) (0.4, 19.4, 64.2)
Adjusted patellab 32.3 ± 19.1 29.5 ± 16.5 0.14
(–6.9, 28.5, 158.7) (–14.4, 25.7, 79.8)
Patella–tibia differenceb 10 ± 12.5 9.2 ± 11.6 0.83
(–0.37, 9, 63) (–30, 8, 41)
aNo. (%). bMean ± SD (minimum, median, maximum).was modest (2.55 µg/g). If one considers
membership in the lowest educational class a
proxy for signiﬁcant environmental/occupa-
tional lead exposure, the differences in the β -
coefficients associated with this exposure
with respect to tibia bone lead of the two
ALAD genotypes (as seen in the stratified
regressions) suggest that at high levels of lead
exposure, ALAD 1-2/2-2 individuals absorb
less lead into cortical bone than ALAD 1-1
individuals. An alternative explanation is
that ALAD 1-2/2-2 individuals experience
greater loss of lead from cortical bone than
ALAD 1-1 individuals.
Furthermore, we found an interaction
between patella (trabecular) bone lead and
ALAD genotype with respect to blood lead
levels. ALAD 1-2/2-2 genotype individuals
had a steeper trabecular bone lead–blood
lead relationship, with higher blood lead lev-
els at a given trabecular bone lead level, but
only when trabecular bone lead levels
exceeded around 60 µg/g. Interestingly,
there appears to be a crossover phenomenon,
with the ALAD 1-2/2-2 genotype individuals
showing signiﬁcantly lower blood lead levels
at a given trabecular bone lead level when
blood lead levels were < 60 µg/dL. To our
knowledge, the latter effect has not been
published previously, but there has been lit-
tle other research that has examined both
bone and blood lead levels in relation to
ALAD genotype, and even less in popula-
tions with relatively low levels of exposure.
These particular results are only sugges-
tive, because they are based upon a few
ALAD 1-2/2-2 individuals who had very
high bone lead levels. Nevertheless, this
observation suggests that the ALAD poly-
morphism modiﬁes movement of lead from
bone into blood, with ALAD 1-2/2-2 geno-
type individuals possibly being less prone to
mobilizing bone lead when bone lead levels
are low, and more prone to mobilizing bone
lead when bone lead levels are high. An
alternative explanation could be that ALAD
1-2/2-2 genotype individuals are initially
more likely to store lead in trabecular bone,
but at a certain low saturation point, they
are less likely to store lead in trabecular
bone. Under this hypothesis, the interaction
at higher levels of lead burden, for example,
could be interpreted as reﬂecting lower bone
lead levels at a given blood lead level (with
blood lead deriving mostly from exogenous
sources) rather than higher blood lead levels
at a given bone lead level (with blood lead
deriving mostly from endogenous bone). It
is not possible to distinguish these possibili-
ties given the cross-sectional nature of this
study.
The gene frequency of the ALAD variant
allele in our study was 8%, which is similar
to the 6% among 1,278 children reported in
New York (6) and the 8% among 691 mem-
bers of a construction trade union reported
in the United States (8). However, it was rel-
atively lower than the 11% reported in
Korean lead-exposed workers (n = 308) (18)
and the 13% reported in Germany lead-
exposed workers (n = 202) (6). This is likely
attributable to ethnic variation in allele fre-
quency.
Two studies have suggested that the
ALAD genotype may be a selection factor for
working in lead industries. Should this be
true, it may have implications for the gener-
alizability of findings from occupationally
exposed groups (9,18). Our research, on the
other hand, was conducted in the commu-
nity, and the distribution of the ALAD poly-
morphism conformed closely to the
Hardy-Weinberg equilibrium. Selection sim-
ilar to a healthy worker effect was unlikely in
our study (9,18), and our ﬁndings can prob-
ably be generalized to low lead-exposed pop-
ulations of men.
In in vitro studies, Battistuzzi et al. (3)
examined enzyme activities among different
ALAD MspI genotypes and found that mean
ALAD enzyme activities (± SD; in η /µg Hb)
are similar among ALAD 1-1, 1-2, and 2-2
individuals: 52 ± 17 (n = 195), 49 ± 20 (n =
43), and 55 ± 7 (n = 5). Subsequently,
Bergdahl et al. (5) found that the presence of
the ALAD-2 subunit was associated with
more bound lead when they studied seven
homozygous wild-type and seven (ALAD)
homozygous variant individuals who were
lead-exposed workers with blood lead levels
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Table 2. Predictors of tibia lead (µg/g) among all subjects in the Normative Aging Study, 1991–1995 (n =
689) 
Model A Model B
Variable Parameter estimate 95% CI Parameter estimate 95% CI
Intercept 18.55 19.01
Genotype
(ALAD 1-2/2-2 vs. ALAD 1-1) –2.55 –5.05––0.05
Age (years) 0.71 0.58–0.84 0.71 0.58–0.84
Education
≤ High school 7.98 5.87–10.09 7.98 5.87–10.09
Some technical school 2.88 –0.16–5.91 2.96 –0.07–5.99
Missing 3.43 –1.51–8.36 3.28 –1.65–8.21
Cumulative smoking (pack-years)
1–20 2.13 –0.35–4.61 2.05 –0.43–4.52
> 20 4.75 2.63–6.88 4.59 2.47–6.71
No information –0.90 –5.39–3.58 –1.00 –5.48–3.47
Alcohol
≥ 2 drinks/day –1.04 –3.29–1.21 –1.11 –3.36–1.14
Vitamin D (IU/day)
179–262 –4.71 –7.37––2.05 –4.79 –7.45––2.13
262–375 –5.00 –7.89––2.11 –4.90 –7.78––2.01
375–589 –3.98 –6.87––1.10 –3.88 –6.75––1.00
> 589 –3.44 –5.99––0.90 –3.55 –6.09––1.01
Total model R 2 0.27 0.27
Table 3. Predictors of patella lead (µg/g) among all subjects in the Normative Aging Study, 1991–1995 (n =
689)
Model A Model B
Variable Parameter estimate 95% CI Parameter estimate 95% CI
Intercept 25.76 25.94
Genotype
(ALAD 1–2/2–2 vs. ALAD 1–1) –1.01 –4.55–2.54
Age (years) 0.89 0.71–1.08 0.90 0.71–1.08
Education
≤ High school 10.23 7.17–13.29 10.24 7.18–13.30
Some technical school 3.51 –0.79–7.80 3.50 –0.80–7.80
Missing 11.72 4.91–18.53 11.69 4.87–18.50
Cumulative smoking (pack-years)
1–20 2.13 –1.44–5.69 2.10 –1.46–5.67
> 20 6.63 3.40–9.85 6.59 3.37–9.82
No information 2.83 –3.51–9.16 2.75 –3.60–9.09
Alcohol
≥ 2 drinks/day 1.93 –1.37–5.23 1.88 –1.43–5.19
Vitamin D (IU/day)
179–262 –7.10 –10.83––3.27 –7.08 –10.86––3.30
262–375 –5.49 –9.59––1.39 –5.46 –9.56––1.35
375–589 –4.80 –8.90––0.70 –4.75 –8.86––0.64
> 589 –5.27 –9.34––1.19 –5.26 –9.33––1.18
Total model R2 0.19 0.19around 30 µg/dL. No significant difference
was found in ALAD lead-binding among 20
unexposed controls whose blood lead levels
were around 4 µg/dL. It is possible that the
difference in ALAD-bound lead in erythro-
cytes may be detectable only at higher lead
levels. In this case, the ALAD-2 protein may
either bind lead more tightly than the
ALAD-1 protein or have more binding sites.
Alternatively, the lack of difference may be
explained simply by the difﬁculty inherent in
quantitating binding at low lead levels (5).
Ziemsen et al. (7) examined blood lead
levels in different ALAD genotypes among
202 lead-exposed workers whose mean (±
SD) (µg/dL) blood lead levels were 40 (± 17)
(7). They found that blood lead levels (mean
± SD, µg/dL) among the ALAD 1-1 (n =
160), ALAD 1-2 (n = 32), ALAD 2-2 (n =
10) groups were 38 ± 17, 44 ± 17, and 56 ±
18, respectively, although these were not sig-
niﬁcantly different. Wetmur et al. (6) exam-
ined the association of ALAD genotype and
blood lead levels among 202 lead workers in
Germany and 1,278 children in New York.
They found that the blood lead levels among
ALAD-2 carriers had median values that
were about 9 to 11 µg/dL greater than simi-
larly exposed individuals who were homozy-
gous for the ALAD-1 allele. These findings
suggested that the ALAD-2 polypeptide
binds lead more tightly and effectively than
ALAD-1. These studies had mean blood lev-
els that were higher than 20 and 40 µg/dL
among environmentally exposed children
and lead-exposed workers, respectively.
Smith et al. (8) investigated the association
between the presence of ALAD-2 allele and
lead concentrations in blood and bone
among 688 members of a construction trade
union. They did not ﬁnd a signiﬁcant differ-
ence in mean blood lead concentrations
between ALAD-2 carriers (n = 96; mean ±
SD, 7.7 ± 3.5 µg/dL) and those homozygous
for the ALAD-1 allele (n = 592; mean ± SD,
7.8 ± 3.6 µg/dL). However, they found a
borderline statistically significant difference
(p = 0.06) by subtracting the tibia lead con-
centrations from the patella lead concentra-
tions for each subject between these two
groups (ALAD-2 carriers: n = 21; mean ±
SD, 8.6 ± 9.5 µg/g; homozygous ALAD-1
allele: n = 101; mean ± SD, 3.4 ± 12.0 µg/g)
among a subset of 122 study subjects. Blood
lead levels in the union members were rela-
tively low (mean ± SD, 7.8 ± 3.6 µg/dL),
and the authors suggested that ALAD poly-
morphism may modify lead kinetics but
only at higher blood lead levels, which
would be consistent with the in vitro study
by Bergdahl et al. (5). 
Recently, two studies investigated the
modulating effect of ALAD polymorphism
on both blood and bone lead in lead smelter
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Table 4. Predictors of tibia lead (µg/g) among participants in the Normative Aging Study, 1991–1995, strati-
ﬁed by genotype. 
Model C Model D
ALAD 1-1 (n = 580) ALAD 1-2/2-2 (n = 109)
Variable Parameter estimate 95% CI Parameter estimate 95% CI
Intercept 18.64 19.51
Age (years) 0.75 0.60–0.89 0.44 0.17–0.72
Education
≤ High school 8.15 5.79–10.50 4.88 0.17–9.58
Some technical school 2.64 –0.78–6.07 3.69 –2.58–9.95
Missing 3.19 –2.10–8.49 3.61 –11.37–18.59
Cumulative smoking (pack-years)
1–20 1.90 –0.90–4.69 3.79 –1.42–9.00
> 20 4.70 2.31–7.08 3.92 0.58–8.42
No information –0.12 –5.12–4.88 –4.14 –14.27–5.99
Alcohol
≥ 2 drinks/day –0.97 –3.44–1.50 –1.63 –7.08–3.82
Vitamin D (IU/day)
179–262 –4.58 –7.49––1.66 –4.91 –11.49–1.67
262–375 –4.55 –7.81––1.28 –6.50 –12.33––0.68
375–589 –3.92 –7.16––0.68 –3.26 –9.23–2.71
> 589 –3.14 –5.97––0.30 –7.31 –13.26––1.36
Total model R2 0.28 0.22
Table 5. Predictors of patella lead (µg/g) among participants in the Normative Aging Study, 1991–1995,
stratiﬁed by genotype. 
Model C Model D
ALAD 1-2 (n = 580) ALAD 1-2/2-2 (n = 109)
Variable Parameter estimate 95% CI Parameter estimate 95% CI
Intercept 26.01 23.22
Age (years) 0.91 0.71–1.12 0.83 0.42–1.23
Education
≤ High school 9.69 5.79–10.50 12.44 5.58–19.30
Some technical school 2.98 –1.81–7.77 5.86 –3.79–15.50
Missing 11.12 –2.10–8.49 14.88 –3.50–33.27
Cumulative smoking (pack-years)
1–20 2.42 –1.62–6.46 2.67 –4.96–10.30
> 20 7.36 3.71–11.02 4.34 –2.53–11.21
No information 4.72 –2.24–11.67 –8.07 –24.85–8.70
Alcohol
≥ 2 drinks/day 1.84 –1.79–5.47 2.35 –6.05–10.75
Vitamin D (IU/day)
179–262 –7.26 –11.40––3.12 –5.76 –15.47–3.95
262–375 –5.11 –9.74––0.47 –7.02 –15.75–1.71
375–589 –6.40 –11.30––1.76 1.94 –6.93–10.82
> 589 –4.65 –9.20––0.11 –6.37 –15.71–2.98
Total model R 2 0.19 0.27
Table 6. Predictors of blood lead (µg/dL) among participants in the Normative Aging Study, 1991–1995,
stratiﬁed by genotype. 
Model D Model E
ALAD 1-1 (n = 580) ALAD 1-2/2-2 (n = 109)
Variable Parameter estimate 95% CI Parameter estimate 95% CI
Intercept 5.12 3.48
Patella lead (µg/g) 0.07 0.05–0.09 0.15 0.10–0.19
Genotype
(ALAD 1-1 vs. ALAD 1-2/2-2)
Interaction
Also in model: age, smoking, alcohol ingestion, vitamin C intake, iron intake.
Table 7. Predictors of blood lead (µg/dL) among all subjects in the Normative Aging Study, 1991–1995 (n =
689).
Model A Model B Model C
Parameter Parameter Parameter
Variable estimate 95% CI estimate 95% CI estimate 95% CI
Intercept 4.90 4.95 5.19
Patella lead (µg/g) 0.08 0.07–0.10 0.08 0.07–0.10  0.07 0.06–0.09
Genotype
(ALAD 1-1 vs. ALAD 1-2/2-2) –0.27 –1.05–0.50 –2.24 –3.83––0.65
Interaction 0.06 0.02–0.11
Also in model: age, smoking, alcohol ingestion, vitamin C intake, iron intake.workers (9,10). The average blood lead levels
in both groups of lead smelter workers were
approximately 20–30 µg/dL, which is higher
than in our study (mean, 6.2 µg/dL) (Tables
2 and 4). Bergdahl et al. (9) did not ﬁnd any
signiﬁcant association between ALAD geno-
type and blood or bone lead levels among 89
lead-exposed workers. They also examined
34 unexposed workers whose median blood
lead level was 4 µg/dL and found no differ-
ence in blood lead levels between 24 ALAD
1-1 and 10 ALAD 1-2 individuals. Because
the sample size was small in this study, it is
difficult to interpret these findings.
However, the authors did ﬁnd that the con-
centrations of urinary calcium and the ratio
of urinary creatinine/serum creatinine were
signiﬁcantly lower in 7 ALAD 1-2/2-2 than
those of 82 ALAD 1-1 lead workers [medi-
ans: urinary calcium (milligrams per liter) 76
vs. 188; the ratio urinary creatinine/serum
creatinine 84 vs. 180]. This study suggested
the presence of ALAD allele-specific differ-
ences in kidney function.
In another study, Fleming et al. (10)
found the average blood lead levels were
22.9 ± 0.4 and 25.2 ± 1.0 µg/dL in 303
ALAD 1-1 and 65 ALAD 1-2/2-2 active lead
workers (p < 0.05). But they did not find
any signiﬁcant difference in tibia bone lead
by genotype (mean ± SD, 41.2 ± 1.8 in
ALAD 1-1 and 42.7 ± 3.4 in ALAD 1-2/2-
2). In addition, they did not ﬁnd any appar-
ent difference in the contribution of bone
lead (either tibia or calcaneus lead) to blood
lead levels by genotype. However, using a
cumulative blood lead index (CBLI) for each
worker, on the basis of individual blood lead
histories and bone lead measurements to
estimate total lead body burden, they found
in linear regressions that the slopes of bone
lead to CBLI were steeper among ALAD 1-1
workers. The more efficient uptake of lead
from blood into the bone of workers with
the ALAD 1-1 genotype is consistent with
our ﬁndings and suggests a decreased trans-
fer of blood lead into bone in ALAD 1-2/2-2
lead workers (10). 
In our study, we found that patella lead
is the major predictor of blood lead in this
aging community-exposed population and
that the ALAD polymorphism significantly
modiﬁes this association. When patella lead
was > 60 µg/g, blood lead levels in ALAD 2
carriers were higher than those in ALAD 1-1
individuals. However, when patella lead was
< 40 µg/g, blood lead levels in ALAD 1-1
individuals were higher than that in ALAD 2
carriers. Our results imply that when blood
lead levels are relatively low (< about 8
µg/dL), ALAD 1-1 individuals will have
higher blood lead levels than ALAD 2 carri-
ers. This ﬁnding suggests that the modulat-
ing effect of the ALAD polymorphism on
blood lead depends on the bone lead bur-
den. Again, the ﬁnding is tentative and must
be verified in other community-exposed
population studies.
We conclude that the ALAD polymor-
phism may modify the exchange of lead
between blood and bone. This, in turn, may
modify an individual’s ultimate risk for toxic-
ity. Indeed, several studies have found that
this ALAD polymorphism modifies indica-
tors of possible lead toxicity, such as kidney
function (8,9) and reproductive (20) and
neuropsychologic function (21). The net
effect on clinical function of the ALAD-2
allele may be detrimental [e.g., on renal func-
tion, as seen by Bergdahl et al. (9) and Smith
et al. (8)] or protective [e.g., on neuropsycho-
logic function, as seen by Bellinger et al. (21)
and on sperm count as seen by Alexander et
al. (20)], possibly depending on the impact
of this polymorphism on the tissue distribu-
tion of lead. Further research is needed to
define precisely the mechanism of function
and the potential impact of the ALAD poly-
morphism on lead kinetics and toxicity.
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Figure 1. Smoothed line of blood lead versus
patella lead by genotypes in 689 community-
exposed men, with adjustment for age, alcohol
consumption, current smoking, vitamin C intake,
and iron intake: the Normative Aging Study,
1991–1995.